A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Inclusion Criteria:

- Histologically confirmed squamous advanced NSCLC (Stage IV).

- Participants must have progressed on one prior line of platinum-based chemotherapy in
the advanced or metastatic setting.

- Measurable disease as measured by response evaluation criteria in solid tumors
(RECIST) criteria v 1.1.

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

- Able to swallow the study drugs whole.

- Adequate organ function.

- Women of childbearing potential must have a negative serum or urine pregnancy test
performed ≤ 7 days prior to start of treatment. Women of childbearing potential or men
with partners of childbearing potential must use effective birth control measures
during treatment and during the 3 months following completion of study treatment.

Exclusion Criteria:

- Participants who have received > 1 prior line of chemotherapy in the advanced or
metastatic setting. (Immunotherapy will not be considered a line of chemotherapy.)

- Prior treatment with a PI3K/mTOR inhibitor, epidermal growth factor receptor (EGFR)
inhibitor, and/or necitumumab.

- History of brain metastases unless irradiated ≥ 2 weeks prior to first study treatment
and stable without requirement of corticosteroids.

- Have serious pre-existing medical conditions.

- Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes mellitus
are eligible if adequate control of blood glucose level is obtained by oral
anti-diabetics.

- Women who are pregnant or breast-feeding.

- Clinically significant electrolyte imbalance ≥ Grade 2.

- Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular
weight heparin and oral Xa inhibitors are allowed.

- Have initiated treatment with bisphosphonates or approved receptor activator of
nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ≤ 28 days
prior to Day 1 of Cycle 1.

- Concurrent serious infection requiring parenteral antibiotic therapy.

- Have a second primary malignancy that in the judgment of the investigator and Medical
Monitor may affect the interpretation of results.

- Have an active, known fungal, bacterial, and/or known viral infection.

- History of arterial or venous embolism within 3 months prior to study enrollment. If
the embolism occurred >3 and <6 months, the participant is eligible provided
appropriate treatment according to institutional standard of care is ensured.